Sun, Nov 24, 2024
[Archive]
Volume 5, Issue 3 (Aug 2020)
JNFS 2020, 5(3): 282-289 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hosseinzadeh M, Pakravanfar F, Ghadiri-Anari A, Fallahzadeh H. The Effect of L-Carnitine Supplementation on Weight and Body Composition in Women with Polycystic Ovary Syndrome: A Double-Blind Randomized Clinical Trial. JNFS 2020; 5 (3) :282-289
URL: http://jnfs.ssu.ac.ir/article-1-298-en.html
URL: http://jnfs.ssu.ac.ir/article-1-298-en.html
Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract: (2640 Views)
Background: Polycystic ovarian syndrome (PCOS), one of the most common causes of endocrine disorders with irregular menstruation, is accompanied by an increase in androgen and polycystic ovarian. The aim of this study was to evaluate the effect of weight loss regimen with and without supplementation.
L-carnitine affects lipid profile, insulin, and hormone resistance indices. Methods: This double-blind randomized clinical trial was conducted over women within the age range of 18 to 45 years, who referred to Yazd Diabetes Center in 2019. The participants were divided into the experimental and control groups. The intervention group received 1000 mg L-carnitine (LG = 28) and the placebo group (PG = 28) received the placebo daily. All people followed a low celery diet for 12 weeks. Anthropometric indices and body composition (weight, body mass index, waist circumference, hip circumference, fat mass, and free fat mass) were measured prior to and after the intervention. Data analysis was performed using SPSS software version 22. The independent sample t-test was used to compare the mean changes between the LG and PG. Results: At the end of the study period, patients treated with L-carnitine showed a significant decrease in waist circumference compared to the PG (change: -1 ± 3.15, P = 0.001) and no significant difference was observed between the two groups in terms of other anthropometrics indices and body composition including fat mass, body mass index, and hip circumference (P > 0.05). Conclusion: The present study showed that 1000 mg oral L-carnitine had no significant effect on body weight, body mass index, body composition, and hip circumference, but had a significant effect on waist circumference size
L-carnitine affects lipid profile, insulin, and hormone resistance indices. Methods: This double-blind randomized clinical trial was conducted over women within the age range of 18 to 45 years, who referred to Yazd Diabetes Center in 2019. The participants were divided into the experimental and control groups. The intervention group received 1000 mg L-carnitine (LG = 28) and the placebo group (PG = 28) received the placebo daily. All people followed a low celery diet for 12 weeks. Anthropometric indices and body composition (weight, body mass index, waist circumference, hip circumference, fat mass, and free fat mass) were measured prior to and after the intervention. Data analysis was performed using SPSS software version 22. The independent sample t-test was used to compare the mean changes between the LG and PG. Results: At the end of the study period, patients treated with L-carnitine showed a significant decrease in waist circumference compared to the PG (change: -1 ± 3.15, P = 0.001) and no significant difference was observed between the two groups in terms of other anthropometrics indices and body composition including fat mass, body mass index, and hip circumference (P > 0.05). Conclusion: The present study showed that 1000 mg oral L-carnitine had no significant effect on body weight, body mass index, body composition, and hip circumference, but had a significant effect on waist circumference size
Type of article: orginal article |
Subject:
public specific
Received: 2020/01/28 | Published: 2020/07/27 | ePublished: 2020/07/27
Received: 2020/01/28 | Published: 2020/07/27 | ePublished: 2020/07/27
References
1. Askarpour M, et al. 2020. Beneficial Effects of L-Carnitine Supplementation for Weight Management in Overweight and Obese Adults: An Updated Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Pharmacological Research. 151: 104554.
2. Azziz R 2004. PCOS: a diagnostic challenge. Reproductive biomedicine online. 8 (6): 644-648.
3. Bahmani F, Karamali M, Shakeri H & Asemi Z 2014. The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled clinical trial. Clinical Endocrinology. 81 (4): 582-587.
4. Barzegar A, Panahi F & Karamzad N 2013. Effect of L-carnitine supplementation on serum adipokines (leptin and visfatin) levels in obese type II diabetes mellitus women with hypocaloric diet. Life Science Journal. 10: 359-365.
5. Center SA, et al. 2000. The clinical and metabolic effects of rapid weight loss in obese pet cats and the influence of supplemental oral L‐carnitine. Journal of Veterinary Internal Medicine. 14 (6): 598-608.
6. Center SA, et al. 2012. Influence of dietary supplementation with (L)-carnitine on metabolic rate, fatty acid oxidation, body condition, and weight loss in overweight cats. American Journal of Veterinary Research. 73 (7): 73, 1002.
7. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ & Mann JI 2006. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disorders. Bipolar Disorders. 8 (5p1): 503-507.
8. Emekçi Özay Ö, Özay AC, Çağlıyan E, Okyay RE & Gülekli B 2017. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecological Endocrinology. 33 (7): 524-528.
9. Fenkci SM, Fenkci V, Oztekin O, Rota S & Karagenc N 2008. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Human Reproduction. 23 (7): 1602-1606.
10. Foroozanfard F, et al. 2015. Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Experimental and Clinical Endocrinology & Diabetes. 123 (04): 215-220.
11. Forouzanfar MH, et al. 2014. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Archives of Iranian Medicine. 17 (5): 304.
12. Ismail AM, Hamed AH, Saso S & Thabet HH 2014. Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 180: 148-152.
13. Jamilian H, et al. 2017. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinology. 33 (6): 442-447.
14. Jamilian M, et al. 2016. The effects of chromium supplementation on endocrine profiles, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biological Trace Element Research. 172 (1): 72-78.
15. Jiskoot G, et al. 2017. A three-component cognitive behavioural lifestyle program for preconceptional weight-loss in women with polycystic ovary syndrome (PCOS): a protocol for a randomized controlled trial. Reproductive Health. 14 (1): 34.
16. Knochenhauer E, et al. 1998. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology & Metabolism. 83 (9): 3078-3082.
17. Kumar NS, Kalaivanam K, Bheemasen R, Chandrappa MS & Ramadas D 2015. A view of L-carnitine in health and disease. journal of Pharmaceutical Research. 5 (8).
18. Legro RS 2012. Obesity and PCOS: implications for diagnosis and treatment. In Seminars in reproductive medicine, pp. 496-506. Thieme Medical Publishers.
19. Molfino A, et al. 2010. Caloric restriction and L-carnitine administration improves insulin sensitivityin patients with impaired glucose metabolism. Journal of Parenteral and Enteral Nutrition. 34 (3): 295-299.
20. Movahedi A 1999. Simple formula for calculating basal energy expenditure. Nutrition Research. 19 (7): 989-995.
21. Pal L, et al. 2012. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecological Endocrinology. 28 (12): 965-968.
22. Panidis D, et al. 2008. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertility and Sterility. 89 (4): 899-906.
23. Pooyandjoo M, Nouhi M, Shab-Bidar S, Djafarian K & Olyaeemanesh A 2016. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. докринологія. 23 (1): 83-90.
24. Rafraf M, Karimi M, Rashidi M & Jafari A 2012. Effect of l-carnitine supplementation in comparison with moderate aerobic training on insulin resistance and anthropometric indices in obese women. Journal of Advances in Medical and Biomedical Research. 20 (83): 17-30.
25. Razavi M, et al. 2016. Selenium supplementation and the effects on reproductive outcomes, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome. Hormone and Metabolic Research. 48 (03): 185-190.
26. Sadeghi A, Djafarian K, Mohammadi H & Shab-Bidar S 2017. Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 11 (2): 157-162.
27. Samimi M, et al. 2016. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled trial. Clinical endocrinology. 84 (6): 851-857.
28. Seim H, Kiess W & Richter T 2002. Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults. Metabolism-Clinical and Experimental,. 51 (11): 1389-1391.
29. Sirmans S & Pate K 2014. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clinical Epidemiology. 6 (1): 1.
30. Teede H, Deeks A & Moran L 2010. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine. 8 (1): 41.
31. Villani RG, Gannon J, Self M & Rich P 2000. L-Carnitine supplementation combined with aerobic training does not promote weight loss in moderately obese women. International Journal of Sport Nutrition and Exercise Metabolism, . 10 (2): 199-207.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
